Sometimes, you have to go it alone. For a while, at least. The mantra across biotech has long been clear: engage your CDMO early, and let those experts guide you into manufacturing. Matthieu de Kalbermatten, CEO of CellProthera, a regenerative cell-therapy developer, begs to differ.
- How To Implement Post-Approval Changes On A Global Level
- March 2026 — CDMO Opportunities And Threats Report
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
- Mastering Biotech's Insourcing/Outsourcing Trade-Offs
- From Principles To Practice: Building Quality Into Generative AI-Assisted Pharma Operations
- Mitigating Challenges In Solid Tumor Delivery
- From QM To QMM For AI-Assisted Pharmaceutical Manufacturing Operations
- The Systems And Choreography Needed For Grade B ATMP Material Transfer
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
5 Steps To Design A Microbiological Performance Qualification For Facilities
Explore five steps to design an EMPQ for sterile manufacturing: classification, protocol drafting, cleaning evaluation, disinfectant efficacy testing, and continuous improvement.
-
Study Viral Infection In Resting Humans CD4+ T Cells With Synthetic sgRNAs
Discover how Synthego's proprietary synthetic sgRNA, combined with Lonza’s 4D-Nucleofector®, enabled highly efficient gene editing in resting human CD4+ T cells.
-
A Novel Cell-Based Assay For Ubiquitin Drug Discovery
Learn about a novel cell-based assay that can advance ubiquitin ligase drug discovery. This high-throughput method simplifies assay development, saving time and resources.
-
Revolutionizing Drug Discovery From "Undruggables" To AI
Explore four current trends in drug discovery, how each trend addresses some of the most crucial challenges in drug discovery, and the obstacles to their widespread adoption.
-
Enhanced Development Of Virus-Specific Hybridomas
Double-stranded DNA viruses cause various human diseases, which complicates diagnosis due to antigen conservation. Explore a cell line that produces specific monoclonal antibodies to aid biotherapeutics development.
-
A Beginner's Guide To Sf9 Culture In Stirred-Tank Bioreactors
Learn about the workflow steps for Sf9 cell expansion, virus preparation, and protein production in stirred-tank bioreactors, including GFP expression.
-
Flow Cytometric Analysis: Differentiation Potential Of Human Stem Cells
Explore an assay kit that simplifies handling with a methylcellulose-free medium and clear flow cytometric readout, which enhances automation and high-throughput sample acquisition for versatile research.
-
Business Continuity Management: The Benzonase® Endonuclease Success Story
Business continuity management is a key success contributor to the pharma industry. Explore best practices for a robust supply chain and how they can translate into success stories.
-
CQA Assessment Of LNP-Encapsulated IVT mRNA
Learn more about issued guidelines on Critical Quality Attributes for IVT mRNA vaccines and biotherapeutics to focus on drug substance and LNP-encapsulated drug product assessment using an analyzer system.
-
Cell Culture Media Mixing In A Benchtop Single-Use Mixer
Explore how efficient powder-liquid mixing and sterile filtration preserve media integrity and support reproducibility in biopharmaceutical workflows, with promising scalability for larger-volume applications.
NEWSLETTER ARCHIVE
- 04.16.26 -- Cell & Gene Capabilities That You Need to Know
- 04.16.26 -- Prioritizing Quality, Fit, And Supplier Reliability In CGT Materials
- 04.15.26 -- Faster, More Efficient Cell & Gene Therapy Workflows with ddPCR
- 04.15.26 -- Mitigating Challenges In Solid Tumor Delivery
- 04.14.26 -- Innovation That's Redefining Aseptic Filling
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections